p38 MAPK Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S1076	SB203580 (Adezmapimod)	Adezmapimod (SB203580, RWJ 64809, PB 203580) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.	Cell Res, 2025, 10.1038/s41422-025-01085-9 Cell Mol Immunol, 2025, 22(5):541-556 Nat Cancer, 2025, 6(2):259-277
S1077	SB202190	SB202190 is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. This compound inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. It significantly suppresses Erastin‐dependent ferroptosis.	Cancer Cell, 2025, S1535-6108(25)00271-5 Nat Cancer, 2025, 6(2):259-277 Nat Metab, 2025, 7(10):2018-2032
S1574	Doramapimod (BIRB 796)	Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays. It binds p38α with K_d of 0.1 nM in THP-1 cells, showing 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, and insignificant inhibition of ERK-1, SYK, IKK2.	Nat Cancer, 2025, 6(2):259-277 Nat Commun, 2025, 16(1):3319 Nat Commun, 2025, 16(1):1834
S1494	Ralimetinib (LY2228820) dimesylate	Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.	Nat Cancer, 2025, 6(2):259-277 Nat Commun, 2025, 16(1):4325 J Exp Clin Cancer Res, 2025, 44(1):269
S2726	PH-797804	PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.	Nat Cancer, 2025, 6(2):259-277 J Exp Clin Cancer Res, 2025, 44(1):273 J Biol Chem, 2025, 301(8):110402
S6005	VX-702	VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β.	Cell Rep Med, 2025, 6(1):101917 World Allergy Organ J, 2025, 18(8):101089 Biol Pharm Bull, 2025, 48(2):172-176
S7215	Losmapimod	Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively. P38 MAPKs are involved in cell differentiation, apoptosis and autophagy. Phase 3.	J Neuroinflammation, 2025, 22(1):32 Nat Commun, 2024, 15(1):987 Int J Mol Sci, 2024, 25(13)7302
S7741	SB239063	SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.	Korean J Physiol Pharmacol, 2024, 28(6):503-513 Cancers (Basel), 2023, 15(3)961 J Pain, 2023, S1526-5900(23)00013-5
S1458	Neflamapimod (VX-745)	Neflamapimod (VX-745) is a potent and selective inhibitor of p38α with IC50 of 10 nM, exhibiting 22-fold greater selectivity versus p38β and no inhibition to p38γ.	Cell Rep, 2025, 44(1):115205 Biology (Basel), 2022, 11(1)121 Biology, 2022, 121
S8124	BMS-582949	BMS-582949 (PS540446) is a potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13nM, inhibiting both p38 kinase activity and activation of p38.	Cell Mol Life Sci, 2024, 82(1):14 Mol Med Rep, 2023, 27(2)47 Molecular Medicine Reports, 2023, 47
S7214	Skepinone-L	Skepinone-L (CBS3830) is a selective p38α-MAPK inhibitor with IC50 of 5 nM.	Immunology, 2025, NONE Journal of Biological Chemistry, 2023, 104699 J Biol Chem, 2023, S0021-9258(23)00341-1
S2928	TAK-715	TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.	bioRxiv, 2025, 2025.02.01.636075 Life (Basel), 2023, 13(2)412 Chem Biol Interact, 2022, 363:110010
S7799	Pexmetinib	Pexmetinib is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.	Journal of Bone Oncology, 2022, 100439 J Bone Oncol, 2022, 35:100439 Theranostics, 2021, 11(4):1626-1640
S8125	Pamapimod	Pamapimod (R-1503, Ro4402257) is a novel, selective inhibitor of p38 mitogen-activated protein kinase. It inhibits p38α and p38β enzymatic activity with IC50 values of 0.014±0.002 and 0.48± 0.04 microM, respectively with no activity against p38delta or p38gamma isoforms.	J Leukoc Biol, 2020, 10.1002/JLB.3A0120-379RR J Pharmacol Exp Ther, 2020, 374(3):489-498 Nat Commun, 2019, 10(1):688
S5183	PD 169316	PD 169316 is a potent, selective and cell-permeable p38 MAP kinase inhibitor with IC50 of 89 nM. PD169316 abrogates signaling initiated by both TGFbeta and Activin A. PD169316 shows antiviral activity against Enterovirus71.	Journal of Dairy Science, 2026, 795-809 J Dairy Sci, 2025, S0022-0302(25)00833-1 PLoS One, 2021, 16(5):e0252541
S0542	R1487	R1487 is an orally bioavailable and highly selective inhibitor of p38α with an ic50 value of 10 nM.	Drug Testing and Analysis, 2021, 283-298 Drug Test Anal, 2020, 10.1002/dta.2917
S3888	3,4',5-Trimethoxy-trans-stilbene	3,4',5-Trimethoxy-trans-stilbene (MR-3) is a methylated derivative of resveratrol and shows more potent inhibitory effects on the growth of human cancer cells (HT-29, PC-3, COLO 205) with IC50 values of 81.31, 42.71 and 6.25 μM, respectively.	Journal of Cell Science, 2025, jcs262255 J Cell Sci, 2025, 138(6)jcs262255
S6502	SD 0006	SD0006 is an inhibitor of p38 kinase-alpha (p38alpha) with IC50 values of 0.016 μM and 0.677 μM for p38α and p38β. It is selective for p38α kinase over 50 other kinases screened (including p38γ and p38δ with modest selectivity over p38β).	Eur Rev Med Pharmacol Sci, 2020, 24(21):10966-10974
E2372	p38-α MAPK-IN-1	p38-α MAPK-IN-1 is an inhibitor of p38-α, with IC50 value of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay.
E5786	SB 202190 hydrochloride	SB 202190 hydrochloride is a selective inhibitor of p38 MAP kinase with IC50 values of 50 nM for p38α and 100 nM for p38β2. It exhibits anti-cancer activity, induces autophagy, and is studied for its role in hippocampus-dependent spatial memory and apoptotic regulation under chronic ischemia.
E3328	Suberect spatholobus stem Extract	Suberect spatholobus stem Extract is extracted from Suberect spatholobus stem, which can Inhibiti TGF-β1/p38MAPK signaling pathway and the synthesis of ColⅠ, thereby playing a role in the treatment of liver fibrosis.
E0114	Dilmapimod (SB-681323)	Dilmapimod (SB-681323,GW 681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
E4791	Adezmapimod hydrochloride	Adezmapimod hydrochloride (RWJ 64809 hydrochloride, SB 203580 hydrochloride) is an inhibitor of the MAPK family member termed as stress-activated protein kinase 2a(SAPK2a; also known as p38). It exhibits IC50 of SAPK2a/p38 and SAPK2b/p38β2 with IC50 values of 50 nM and 500 nM respectively and can be used in research of chronic inflammatory diseases, such as rheumatoid arthritis.
S0387	SB 242235	SB-242235 is a potent and selective p38 MAP kinase inhibitor, inhibits p38 MAP kinase induced by IL-1β with an IC50 of approximately 1.0 μM in primary human chondrocytes.
S0388	SD169	SD-169(5-Carbamoylindole) is a selective inhibitor of p38α MAPK, which can reduce p38 and HSP60 expression in T cells of the pancreatic beta islets.
E2630	SKF-86002	SKF-86002 is an orally active p38 MAPK inhibitor, inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production with IC50 of 1 μM, also inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
S6807	TA-02	TA-02 is a p38 MAPK inhibitor with IC50 of 20 nM. This compound especially inhibits TGFBR-2.
E1938	HRX215	HRX215 (Darizmetinib) is a first-in-class, highly potent, selective, and orally active inhibitor of MKK4 with an IC50 of 0.02 µM. It enhances liver regeneration, prevents liver failure following extensive hepatectomy in pigs, and has potential to prevent liver failure after major oncological liver resections or transplantation of small liver grafts in humans.
E3033	Pulsatillae Extract	Pulsatillae Extract is extracted from Pulsatilla chinensis, major active constituent of which can reduce tumorigenesis, metastasis and immunosuppression of tumor via disruption of the MAPK signaling pathway.
S8706	UM-164	UM-164 is a highly potent, dual c-Src/p38inhibitor of c-Src with a binding constant Kd of 2.7 nM for c-Src and this compound inhibits both p38α and p38β.	Cell Death Dis, 2025, 16(1):351 Cell Death & Disease, 2025, 351 Aquaculture Reports, 2025, 103031
S3940	3'-Hydroxypterostilbene	3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium which may be useful in treating different types of haematological malignancies. This compound, a natural pterostilbene analogue, effectively inhibits the growth of human colon cancer cells (IC50s of 9.0, 40.2, and 70.9 µM for COLO 205, HCT-116, and HT-29 cells, respectively) by inducing apoptosis and autophagy. It inhibits the PI3K/Akt/mTOR/p70S6K, and p38MAPK pathways and activates the ERK1/2, JNK1/2 MAPK pathways.	Int J Mol Sci, 2024, 25(18)9990 International Journal of Molecular Sciences, 2024, 9990 Human Molecular Genetics, 2024, 2133–2144
E7844^New	Tpl2 Kinase Inhibitor 1	Tpl2 Kinase Inhibitor 1 is a 3-pyridylmethylamino derivative that selectively inhibits Tpl2 (IC50=50 nM). Tpl2, also known as COT kinase or MAP3K8, is targeted by this compound which modulates inflammatory responses and influences certain cancer progression pathways.
S8989	Xanthatin	Xanthatin is a sesquiterpene lactone isolated from Xanthium strumarium leaves, which can inhibit the nuclear factor kappa-B (NF-κB), mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STATs) signaling pathways.
S0752	AUDA	AUDA (compound 43) is a potent inhibitor of soluble epoxide hydrolase (sEH) with IC50 of 18 nM and 69 nM for the mouse sEH and human sEH, respectively. This compound has anti-inflammatory activity that reduces the protein expression of MMP-9, IL-1β, TNF-α and TGF-β. It downregulates Smad3 and p38 signaling pathways.
S4884	Trans-Zeatin	Trans-Zeatin ((E)-Zeatin) is the member of the plant growth hormone family known as cytokinins, which regulate cell division, development, and nutrient processing. This compound inhibits UVB-induced MMP-1 expression, c-Jun activation and phosphorylation of ERK, JNK and p38 MAP kinases (MAPKs) dose-dependently.
E3656	Dichroa febrifuga Extract	Dichroa Febrifuga Extract is extracted from Dichroa Febrifuga, which can Suppress PI3K/AKT and MAPK Signaling Pathways.
S9315	Praeruptorin A	Praeruptorin A, a naturally existing pyranocumarin, is isolated from the dried root of Peucedanum praeruptorum Dunn. This compound inhibits p38/Akt-c-Fos-NFATc1 signaling and PLCγ-independent Ca2+ oscillation. It can significantly upregulates multidrug resistance-associated protein 2 expression via the constitutive androstane receptor-mediated pathway in vitro, and this should be taken as an herb-drug interaction.
S6920	SEA0400	SEA0400 is a selective and potent inhibitor of the Na+-Ca2+ exchanger (NCX) that inhibits Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia with IC50 of 33 nM, 5.0 nM and 8.3 nM, respectively. This compound prevents sodium nitroprusside (SNP) from increasing ERK and p38 MAPK phosphorylation and production of reactive oxygen species (ROS) in an extracellular Ca(2+)-dependent manner.
E3365	Weigela Grandiflora Fortune Extract	Weigela Grandiflora Fortune Extract is extracted from Weigela Grandiflora Fortune, which decreases the infection-mediated expression of inflammatory mediators by inhibiting the AKT/NF-κB and MAPK signaling pathways.
S9075	Mulberroside A	Mulberroside A, isolated from the ethanol extract of Morus alba roots, is widely employed as an active ingredient in cosmetic products due to its anti-tyrosinase and anti-oxidant activities. This compound decreases the expressions of TNF-α, IL-1β and IL-6 and inhibits the activation of NALP3, caspase-1 and NF-κB and the phosphorylation of ERK, JNK and p38.
S0186	TA-01	TA-01 is a potent inhibitor of CK1δ/ε and p38 MAPK with IC50 of 6.4 nM, 6.8 nM and 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively.
E2399	Falnidamol	Falnidamol (BIBX1382) is a selective inhibitor of epidermal growth factor receptor (EGFR), exerting anti-cancer role in human head and neck squamous cell carcinomas both in vitro and in vivo through suppressing mitogen-activated protein kinases (MAPKs) signaling.
S6347	5'-N-Ethylcarboxamidoadenosine (NECA)	5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. It acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
E2661	Chitosan oligosaccharide	Chitosan oligosaccharide (COS) is an oligomer of β-(1➔4)-linked d-glucosamine, of which actions involve the modulation of several important pathways including the suppression of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPK) and the activation of AMP-activated protein kinase (AMPK).